129 related articles for article (PubMed ID: 37658751)
1. Paclitaxel-carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series.
Kotaka S; Kondo E; Kawai Y; Okamoto K; Kishigami Y; Yamawaki T; Nagao K; Toru H; Suzuki S
J Obstet Gynaecol Res; 2023 Dec; 49(12):2868-2874. PubMed ID: 37658751
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in patients with recurrent high-grade neuroendocrine cervical cancer: a Neuroendocrine Cervical Tumor Registry (NeCTuR) study.
Frumovitz M; Chisholm GB; Jhingran A; Ramalingam P; Flores-Legarreta A; Bhosale P; Gonzales NR; Hillman RT; Salvo G
Am J Obstet Gynecol; 2023 Apr; 228(4):445.e1-445.e8. PubMed ID: 36516952
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer.
Ilhan Y; Tatli AM; Teker F; Onder AH; Kose F; Geredeli C; Karaagac M; Kaplan MA; Inanc M; Goktas Aydin S; Kargi A; Arak H; Ozturk B; Besen AA; Selvi O; Korkmaz M; Oruc Z; Bozkurt O; Bilici A; Bayram S; Dae SA; Ozdogan M; Coskun HS; Sezgin Goksu S
Int J Gynecol Cancer; 2022 Apr; 32(4):502-507. PubMed ID: 35086927
[TBL] [Abstract][Full Text] [Related]
4. Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer.
Kotaka S; Kondo E; Kawai Y; Okamoto K; Kishigami Y; Yamawaki T; Nagao K; Hirata T; Suzuki S
J Gynecol Oncol; 2023 Sep; 34(5):e60. PubMed ID: 37170726
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
Tanigawa T; Takeshima N; Ishikawa H; Nishio S; Usami T; Yamawaki T; Oishi T; Ihira K; Kato H; Goto M; Saito M; Taira Y; Yokoyama M; Shoji T; Kondo E; Mori A; Yokoi T; Iwasa-Inoue N; Hirashima Y; Nagasawa T; Takenaka M; Mikami M; Sugiyama T; Enomoto T
Gynecol Oncol; 2022 Jun; 165(3):413-419. PubMed ID: 35487773
[TBL] [Abstract][Full Text] [Related]
7. Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).
Ishikawa M; Shibata T; Kataoka T; Takekuma M; Kobayashi H; Yaegashi N; Satoh T;
Int J Gynecol Cancer; 2023 May; 33(5):692-700. PubMed ID: 36997229
[TBL] [Abstract][Full Text] [Related]
8. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer.
Yasunaga M; Yahata H; Okugawa K; Shimokawa M; Maeda Y; Hori E; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K
Taiwan J Obstet Gynecol; 2022 Sep; 61(5):818-822. PubMed ID: 36088050
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study.
Chu G; Liu X; Yu W; Chen M; Dong L
BMC Cancer; 2021 Feb; 21(1):133. PubMed ID: 33549065
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311).
Ishikawa M; Nakamura K; Shibata T; Tanaka K; Kitagawa R; Kobayashi H; Yaegashi N;
Jpn J Clin Oncol; 2018 Dec; 48(12):1096-1100. PubMed ID: 30295796
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine carcinoma of the cervix: a systematic review of the literature.
Tempfer CB; Tischoff I; Dogan A; Hilal Z; Schultheis B; Kern P; Rezniczek GA
BMC Cancer; 2018 May; 18(1):530. PubMed ID: 29728073
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
16. Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer.
Maene C; Salihi RR; Van Nieuwenhuysen E; Han SN; Concin N; Vergote I
Int J Gynecol Cancer; 2021 Jun; 31(6):824-828. PubMed ID: 33858952
[TBL] [Abstract][Full Text] [Related]
17. Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review.
Yang Y; Xu H; Zhang L; Bai L; Zhu H; Li Q
Anticancer Drugs; 2022 Feb; 33(2):214-219. PubMed ID: 34620744
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
[TBL] [Abstract][Full Text] [Related]
19. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review.
Nagao S; Miwa M; Maeda N; Kogiku A; Yamamoto K; Morimoto A; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Sakuma T; Fujiwara K
Int J Gynecol Cancer; 2015 Sep; 25(7):1300-5. PubMed ID: 26166556
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.
Alifieris CE; Griniatsos J; Delis SG; Nikolaou M; Avgoustou C; Panagiotidis MI; Souferi-Chronopoulou E; Trafalis DT
Am J Clin Oncol; 2020 May; 43(5):305-310. PubMed ID: 32343515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
